E-LIB Suche - Ergebnisse für: Bahcall, Magda

1

Activating Point Mutations in the MET Kinase Domain Represe..:

Pecci, Federica ; Nakazawa, Seshiru ; Ricciuti, Biagio...
Cancer Discovery. , 2024

Link: https://doi.org/10.1158/..

2

An allosteric inhibitor against the therapy-resistant mutan..:

To, Ciric ; Beyett, Tyler S. ; Jang, Jaebong...
Nature Cancer. 3 (2022) 4 - p. 402-417 , 2022

Link: https://doi.org/10.1038/..

3

Silent mutations reveal therapeutic vulnerability in RAS Q6..:

Kobayashi, Yoshihisa ; Chhoeu, Chhayheng ; Li, Jiaqi...
Nature. 603 (2022) 7900 - p. 335-342 , 2022

Link: https://doi.org/10.1038/..

4

Chemically Induced Degradation of Anaplastic Lymphoma Kinas..:

Powell, Chelsea E. ; Gao, Yang ; Tan, Li...
Journal of Medicinal Chemistry. 61 (2018) 9 - p. 4249-4255 , 2018

Link: https://doi.org/10.1021/..

5

Discovery of a potent dual ALK and EGFR T790M inhibitor:

Jang, Jaebong ; Son, Jung Beom ; To, Ciric...
European Journal of Medicinal Chemistry. 136 (2017) - p. 497-510 , 2017

Link: https://doi.org/10.1016/..

6

Discovery of Inhibitors That Overcome the G1202R Anaplastic..:

Hatcher, John M. ; Bahcall, Magda ; Choi, Hwan Geun...
Journal of Medicinal Chemistry. 58 (2015) 23 - p. 9296-9308 , 2015

Link: https://doi.org/10.1021/..

7

Combination of type I and type II MET tyrosine kinase inhib..:

Bahcall, Magda ; Paweletz, Cloud P ; Kuang, Yanan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828669/. , 2022

Link: http://www.ncbi.nlm.nih...

8

ERK inhibitor LY3214996-based treatment strategies for RAS-..:

Köhler, Jens ; Zhao, Yutong ; Li, Jiaqi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026682/. , 2021

Link: http://www.ncbi.nlm.nih...

9

Oncogenic switch and single-agent MET inhibitor sensitivity..:

Eser, Pınar Özden ; Paranal, Raymond M ; Son, Jieun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627689/. , 2021

Link: http://www.ncbi.nlm.nih...

10

ERK inhibitor LY3214996-based treatment strategies for RAS-..:

Köhler, Jens ; Zhao, Yutong ; Li, Jiaqi...
info:eu-repo/semantics/altIdentifier/pmid/33536188. , 2021

Link: http://hdl.handle.net/23..

11

Treatment-induced tumor dormancy through YAP-mediated trans..:

Kurppa, Kari J ; Liu, Yao ; To, Ciric...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146079/. , 2020

Link: http://www.ncbi.nlm.nih...

12

Use of ex vivo patient derived tumor organotypic spheroids ..:

Ivanova, Elena ; Kuraguchi, Mari ; Xu, Man...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967092/. , 2020

Link: http://www.ncbi.nlm.nih...

13

Amplification of wild type KRAS imparts resistance to crizo..:

Bahcall, Magda ; Awad, Mark M ; Sholl, Lynette M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279568/. , 2018

Link: http://www.ncbi.nlm.nih...

14

Chemically Induced Degradation of Anaplastic Lymphoma Kinas..:

Powell, Chelsea E ; Gao, Yang ; Tan, Li...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294449/. , 2018

Link: http://www.ncbi.nlm.nih...

15

Response heterogeneity of EGFR and HER2 exon 20 insertions ..:

Kosaka, Takayuki ; Tanizaki, Junko ; Paranal, Raymond M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596996/. , 2017

Link: http://www.ncbi.nlm.nih...